相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles
Eric Volta-Duran et al.
ACTA BIOMATERIALIA (2021)
In Vitro Fabrication of Microscale Secretory Granules
Hector Lopez-Laguna et al.
ADVANCED FUNCTIONAL MATERIALS (2021)
Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4
Victor Pallares et al.
JOURNAL OF CONTROLLED RELEASE (2021)
A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models
Aida Falgas et al.
HAEMATOLOGICA (2020)
Artificial Inclusion Bodies for Clinical Development
Julieta M. Sanchez et al.
ADVANCED SCIENCE (2020)
Engineering Secretory Amyloids for Remote and Highly Selective Destruction of Metastatic Foci
Maria Virtudes Cespedes et al.
ADVANCED MATERIALS (2020)
Nanostructured toxins for the selective destruction of drug-resistant human CXCR4+ colorectal cancer stem cells
Naroa Serna et al.
JOURNAL OF CONTROLLED RELEASE (2020)
An Auristatin nanoconjugate targeting CXCR4+leukemic cells blocks acute myeloid leukemia dissemination
Victor Pallares et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Engineering Protein Venoms as Self-Assembling CXCR4-Targeted Cytotoxic Nanoparticles
Naroa Serna et al.
PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION (2020)
A refined cocktailing of pro-apoptotic nanoparticles boosts anti-tumor activity
Laura Sanchez-Garcia et al.
ACTA BIOMATERIALIA (2020)
Engineering Protein Nanoparticles Out from Components of the Human Microbiome
Hector Lopez-Laguna et al.
SMALL (2020)
Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles
Patricia Alamo et al.
PHARMACEUTICS (2020)
Developing Protein-Antitumoral Drug Nanoconjugates as Bifunctional Antimicrobial Agents
Naroa Serna et al.
ACS APPLIED MATERIALS & INTERFACES (2020)
Divalent Cations: A Molecular Glue for Protein Materials
Hector Lopez-Laguna et al.
TRENDS IN BIOCHEMICAL SCIENCES (2020)
Selective delivery of T22-PE24-H6 to CXCR4+ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model
Aida Falgas et al.
THERANOSTICS (2020)
High-throughput identification of peptide agonists against GPCRs by co-culture of mammalian reporter cells and peptide-secreting yeast cells using droplet microfluidics
KenshiYaginuma et al.
SCIENTIFIC REPORTS (2019)
Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4+ colorectal cancer
Rita Sala et al.
ACTA BIOMATERIALIA (2019)
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
Barbara Muz et al.
BLOOD CANCER JOURNAL (2019)
Assembly of histidine-rich protein materials controlled through divalent cations
Hector Lopez-Laguna et al.
ACTA BIOMATERIALIA (2019)
Engineering a recombinant chlorotoxin as cell-targeted cytotoxic nanoparticles
Raquel Diaz et al.
SCIENCE CHINA-MATERIALS (2019)
Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery
Danielle E. Large et al.
ADVANCED THERAPEUTICS (2019)
2D and 3D cell cultures - a comparison of different types of cancer cell cultures
Marta Kapalczynska et al.
ARCHIVES OF MEDICAL SCIENCE (2018)
Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs
Laura Sanchez-Garcia et al.
JOURNAL OF CONTROLLED RELEASE (2018)
CXCR4 overexpression is correlated with poor prognosis in colorectal cancer
Chao Xu et al.
LIFE SCIENCES (2018)
CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver
Aitor Benedicto et al.
ONCOLOGY REPORTS (2018)
Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin
Raquel Diaz et al.
SMALL (2018)
Protein-Based Therapeutic Killing for Cancer Therapies
Naroa Serna et al.
TRENDS IN BIOTECHNOLOGY (2018)
Selective depletion of metastatic stem cells as therapy for human colorectal cancer
Maria Virtudes Cespedes et al.
EMBO MOLECULAR MEDICINE (2018)
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
M. Abraham et al.
LEUKEMIA (2017)
Taking the vehicle out of drug delivery
Jianliang Shen et al.
MATERIALS TODAY (2017)
Engineering multifunctional protein nanoparticles by in vitro disassembling and reassembling of heterologous building blocks
Ugutz Unzueta et al.
NANOTECHNOLOGY (2017)
Protein-only, antimicrobial peptide-containing recombinant nanoparticles with inherent built-in antibacterial activity
Naroa Serna et al.
ACTA BIOMATERIALIA (2017)
Ligand-Targeted Drug Delivery
Madduri Srinivasarao et al.
CHEMICAL REVIEWS (2017)
Peptide-Based Nanostructured Materials with Intrinsic Proapoptotic Activities in CXCR4+ Solid Tumors
Naroa Serna et al.
ADVANCED FUNCTIONAL MATERIALS (2017)
Chemokines and cocaine: CXCR4 receptor antagonist AMD3100 attenuates cocaine place preference and locomotor stimulation in rats
Jae Kim et al.
BRAIN BEHAVIOR AND IMMUNITY (2017)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
Rational design of fiber forming supramolecular structures
Vivek A. Kumar et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2016)
Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4
Onofrio Zirafi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles
Naroa Serna et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2016)
Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models
Maria Virtudes Cespedes et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2016)
Supramolecular biomaterials
Matthew J. Webber et al.
NATURE MATERIALS (2016)
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment
James R. Kintzing et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances
Gustaw Lech et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Administration of the Dual E-Selectin/CXCR4 Antagonist, GMI-1359, Results in a Unique Profile of Tumor Mobilization from the Bone Marrow and Facilitation of Chemotherapy in a Murine Model of FLT3 ITD AML
William E. Fogler et al.
BLOOD (2016)
Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging
Micah D. K. Glasgow et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2015)
Formulating tumor-homing peptides as regular nanoparticles enhances receptor-mediated cell penetrability
Zhikun Xu et al.
MATERIALS LETTERS (2015)
CXCR4 over-expression and survival in cancer: A system review and meta-analysis
Hongli Zhao et al.
ONCOTARGET (2015)
Discovery and Characterization of an Endogenous CXCR4 Antagonist
Onofrio Zirafi et al.
CELL REPORTS (2015)
In Vivo Architectonic Stability of Fully de Novo Designed Protein-Only Nanoparticles
Maria Virtudes Cespedes et al.
ACS NANO (2014)
Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models
Patricia Alamo et al.
DISEASE MODELS & MECHANISMS (2014)
State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines
Charlene M. Dawidczyk et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Tumor-Antigen-Binding Bispecific Antibodies for Cancer Treatment
Ulrich H. Weidle et al.
SEMINARS IN ONCOLOGY (2014)
A review on CXCR4/CXCL12 axis in oncology: No place to hide
Urszula M. Domanska et al.
EUROPEAN JOURNAL OF CANCER (2013)
Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability
Kirsten Achilles Poon et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2013)
Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles
Ugutz Unzueta et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2012)
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D. Senter et al.
NATURE BIOTECHNOLOGY (2012)
Nanomedicine(s) under the Microscope
Ruth Duncan et al.
MOLECULAR PHARMACEUTICS (2011)
Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide
Esther Vazquez et al.
NANOMEDICINE (2010)
Ligand-based targeted therapy for cancer tissue
Manasi Das et al.
EXPERT OPINION ON DRUG DELIVERY (2009)
CXCR4, inhibitors and mechanisms of action
Xiangyang Liang
CHEMICAL BIOLOGY & DRUG DESIGN (2008)
Therapeutic nanoparticles for drug delivery in cancer
Kwangjae Cho et al.
CLINICAL CANCER RESEARCH (2008)
The challenge of drugging undruggable targets in cancer: Lessons learned from targeting BCL-2 family members
Gregory L. Verdine et al.
CLINICAL CANCER RESEARCH (2007)
Regulation of CXCR4 signaling
John M. Busillo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2007)
Matrix elasticity directs stem cell lineage specification
Adam J. Engler et al.
CELL (2006)
AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates
A Larochelle et al.
BLOOD (2006)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Molecular dynamics simulations on SDF-1 alpha: Binding with CXCR4 receptor
XQ Huang et al.
BIOPHYSICAL JOURNAL (2003)
Endogenous carriers and ligands in non-immunogenic site-specific drug delivery
SP Vyas et al.
ADVANCED DRUG DELIVERY REVIEWS (2000)
分享论文
